Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

RASAL2 Plays Inconsistent Roles in Different Cancers.

Bolun Zhou1, Wei Zhu1, Xingjun Jiang1

  • 1Cancer Research Institute, Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha, China.

Frontiers in Oncology
|December 5, 2019
PubMed
Summary

RASAL2, a protein involved in cancer, acts as both a tumor suppressor and oncogene depending on the cancer type. Understanding its dual role offers new therapeutic targets for various cancers.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Physics-Informed Artificial Intelligence Design of Picomolar Nanobodies Enables Deep Tumor Penetration and High-Contrast Imaging.

Research (Washington, D.C.)·2026
Same author

A multi-omics atlas reveals spatially resolved sphingolipid metabolic reprogramming after spinal cord injury.

Experimental neurology·2026
Same author

A Paradigm Shift in Snakebite Envenoming Therapy: From Conventional Antivenoms to Rationally Designed, Broadly Neutralizing Combination Therapies.

ACS pharmacology & translational science·2026
Same author

ESRG maintains human pluripotent stem cell self-renewal by binding NPM1 to regulate BMP4 protein and TGF-β signaling pathway.

Cell & bioscience·2026
Same author

A triple combination strategy for nasopharyngeal carcinoma: Aptamer-guided liposomal chemotherapy, engineered NK cells, and Fc-enhanced PD-L1 antibody therapy.

Acta pharmaceutica Sinica. B·2026
Same author

Pulmonary macrophage-targeted RNAi and mRNA co-delivery via SORT lipid nanoparticles enhances immunotherapy in lung cancer.

Journal of controlled release : official journal of the Controlled Release Society·2025

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • RAS protein activator like 2 (RASAL2) is a member of the RAS GTPase-activating protein family.
  • RASAL2 has been implicated in numerous cancers, including ovarian, lung, and breast cancer.
  • Its role has shifted from a tumor suppressor to an oncogene in specific cancers like colorectal and liver cancer.

Purpose of the Study:

  • To review the latest findings on RASAL2's role in various cancers.
  • To discuss the dual functions and mechanisms of RASAL2 in cancer progression.
  • To highlight RASAL2 as a potential prognostic factor and therapeutic target.

Main Methods:

  • Literature review of recent studies on RASAL2 in cancer.
  • Analysis of RASAL2's functions, including inhibition of invasion, metastasis, and angiogenesis.
Keywords:
EMTRAS GTPase-activating proteinRASAL2cancerinvasionmetastasis

Related Experiment Videos

  • Examination of RASAL2's correlation with clinical parameters like cancer stage and prognosis.

    • Main Results:

    • RASAL2 exhibits context-dependent roles, acting as a tumor suppressor or oncogene.
    • Its functions vary across different cancer types, affecting invasion, metastasis, and angiogenesis.
    • RASAL2 shows diverse relationships with clinical cancer stage, grade, prognosis, and survival.

    Conclusions:

    • RASAL2 is a significant factor in cancer development and progression.
    • Its dual role presents opportunities for novel cancer treatment strategies.
    • RASAL2 holds potential as a prognostic biomarker and therapeutic target in oncology.